NurExone Biologic

NurExone has developed ExoTherapy, an exosome-based drug-delivery platform, and is advancing ExoPTEN as a therapy for acute spinal cord injuries.

Scientific Article – Golden Exosomes Selectively Target Brain Pathologies

James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic.

NurExone develops first technology drug platform for exosome-based product known as ExoTherapy to treat trauma to the spinal cord and brain.

The Senior Bio-process Manager ensures robust and high-yield manufacturing of the company’s CMC production process.

The Team Leader of the Analytical Method Development team at NurExone develops, optimizes, and validates methods for exosome-based products and assays.

The company seeks neuroscientists specializing in nanoparticles, drug development, RNA-based therapeutics, and analytical method development.

Dr. Halperin is a physician with over 20 years of experience in the pharmaceutical industry and has invested in 10 biotech companies

Israeli entrepreneur and expert in IT and advanced technologies, Gabriel has created several high-tech and biotechnology start-ups.

Mr. James Jay Richardson has served as CEO or Chairman of six listed public companies and in many other CFO and private company situations.

Dr. Lior Shaltiel is an entrepreneur/scientist of chem engineering, molecular bio, electrophysiology, pharmacology, drug delivery systems.

2022 NurExone Business Plan – Executive Summary [will be uploaded soon]

With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress

NurExone is collaborating with Inteligex to expand the Company’s portfolio and to research a combination regenerative therapy for chronic spinal cord injuries.

NurExone's exosome platform delivers targeted regenerative medicine — from spinal cord injury and glaucoma to aesthetics and wellness applications.

NurExone demonstrates that its naïve exosomes and lead drug candidate **ExoPTEN** show therapeutic benefits in preclinical models of optic nerve injury. The findings support progression toward larger animal studies. The company develops exosome-based regenerative therapies.

Oct 2026Business InsiderNews article

NurExone Biologic Inc. reports its second-quarter 2026 financial results, covering the period ending June 30, 2026. The biotech firm, specializing in exosome-based regenerative therapies, also highlights recent corporate activities and upcoming milestones in its update. The announcement follows the company’s ongoing development in advanced medical treatments.

Aug 2026NurExoneNews article

NurExone Biologic reports second-quarter 2026 financial results, covering the period ending June 30. The biotech firm specializes in exosome-based regenerative therapies and highlights recent progress toward upcoming milestones in its corporate update.

Aug 2026BioSpaceNews article

Made Scientific has signed a binding memorandum of understanding (MOU) with NurExone Biologic Inc. to handle U.S. Good Manufacturing Practice (GMP) exosome production and commercial supply. The agreement leverages Made Scientific’s existing facilities and capabilities for exosome manufacturing, supporting NurExone’s operational and distribution needs.

Aug 2026madescientific.comNews article